Trial Profile

Phase III trial of intranasal dexmedetomidine in patients with acute postoperative pain.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 29 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexmedetomidine (Primary)
Indications Postoperative pain
Focus Therapeutic Use
Sponsors Societal CDMO

Most Recent Events

26 Oct 2015 According to Recro Pharma media release, the company has decided not to continue with the clinical program for Dex-IN in post operative pain after feedback from FDA on the phase II efficacy and safety data. It intends to pursue a phase II program in peri-procedural pan instead.
26 Oct 2015 Status changed from planning to withdrawn prior to enrolment, based on the information in the Recro Pharma media release.
27 Mar 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com